Q-omics provides the consensus-scored RBM7 profile across patient tissues and cancer cell-line models. RBM7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RBM7 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RBM7 RNA expression shows 19,637 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where RBM7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM7 survival associations across molecular data types. RBM7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM7 RNA expression–survival associations across cancer types. High RBM7 expression shows unfavorable associations in ACC and CESC, but favorable associations in SKCM, KIRC, COAD and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RBM7 RNA expression.
This table summarizes RBM7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RBM7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM7 shows lower tumor expression in BRCA, THCA, LUSC and KICH and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher RBM7 RNA expression in tumor versus normal tissue (log2 FC = +0.806, t-test p = .002).
This table shows molecular features associated with RBM7 in patient tissues and cancer cell lines. In patient samples, RBM7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
